Elkhamisy Sally A, Valentini Chiara, Lattermann Annika, Radhakrishna Ganesh, Künzel Luise A, Löck Steffen, Troost Esther G C
OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, 01307 Dresden, Germany.
Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Cancers (Basel). 2023 Jul 25;15(15):3771. doi: 10.3390/cancers15153771.
LAPC is associated with a poor prognosis and requires a multimodal treatment approach. However, the role of radiation therapy in LAPC treatment remains controversial. This systematic review aimed to explore the role of proton and photon therapy, with varying radiation techniques and fractionation, in treatment outcomes and their respective toxicity profiles.
Clinical studies published from 2012 to 2022 were systematically reviewed using PubMed, MEDLINE (via PubMed) and Cochrane databases. Different radiotherapy-related data were extracted and analyzed.
A total of 31 studies matched the inclusion criteria. Acute toxicity was less remarkable in stereotactic body radiotherapy (SBRT) compared to conventionally fractionated radiotherapy (CFRT), while in proton beam therapy (PBT) grade 3 or higher acute toxicity was observed more commonly with doses of 67.5 Gy (RBE) or higher. Late toxicity was not reported in most studies; therefore, comparison between groups was not possible. The range of median overall survival (OS) for the CFRT and SBRT groups was 9.3-22.9 months and 8.5-20 months, respectively. For the PBT group, the range of median OS was 18.4-22.3 months.
CFRT and SBRT showed comparable survival outcomes with a more favorable acute toxicity profile for SBRT. PBT is a promising new treatment modality; however, additional clinical studies are needed to support its efficacy and safety.
局部晚期胰腺癌(LAPC)预后较差,需要多模式治疗方法。然而,放射治疗在LAPC治疗中的作用仍存在争议。本系统评价旨在探讨质子和光子治疗在不同放射技术和分割方式下对治疗结果及其各自毒性特征的作用。
使用PubMed、MEDLINE(通过PubMed)和Cochrane数据库对2012年至2022年发表的临床研究进行系统评价。提取并分析不同的放疗相关数据。
共有31项研究符合纳入标准。与传统分割放疗(CFRT)相比,立体定向体部放疗(SBRT)的急性毒性不太明显,而在质子束治疗(PBT)中,当剂量达到67.5 Gy(相对生物效应)或更高时,更常观察到3级或更高的急性毒性。大多数研究未报告晚期毒性;因此,无法进行组间比较。CFRT组和SBRT组的中位总生存期(OS)范围分别为9.3 - 22.9个月和8.5 - 20个月。对于PBT组,中位OS范围为18.4 - 22.3个月。
CFRT和SBRT显示出相当的生存结果,SBRT的急性毒性特征更有利。PBT是一种有前景的新治疗方式;然而,需要更多的临床研究来支持其有效性和安全性。